Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer

Adnan Nagrial*, Lorraine Chantrill, Venessa Chin, Katrin Sjoquist, Chelsie A. O'Connor, Desmond Yip

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

This Cochrane Protocol has been withdrawn from publication. The Cochrane Gut Editorial Team made the decision to withdraw the protocol in agreement with the authors. The title is superseded by another review: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011044.pub2/full. 

This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objective is to conduct a systematic review of the published and unpublished literature to assess the effect of chemotherapy, radiotherapy and biological therapies, either alone or in combination, on overall survival in people with advanced pancreatic carcinoma. We will examine these effects: in the setting of inoperable advanced (including locally advanced and metastatic) or relapsed disease; in the setting of first line or second line treatment. Adverse effects and quality of life data (where available) will be recorded and tabulated. Comparisons will be as follows. Any chemotherapy treatment versus placebo or no treatment or best supportive care. Any chemotherapy treatment versus any chemotherapy treatment. Any biological agent versus placebo or no treatment or best supportive care. Any biological agent versus any biological agent. Any biological agent combined with any chemotherapy treatment versus no treatment or best supportive care. Any biological agent combined with any chemotherapy treatment versus any chemotherapy treatment. Any biological agent combined with any chemotherapy treatment versus any biological agent combined with any chemotherapy treatment. Any radiotherapy treatment versus placebo or no treatment or best supportive care. Any radiotherapy treatment versus any radiotherapy treatment. Any combination of radiotherapy and chemotherapy versus placebo, no treatment or best supportive care. Any combination of radiotherapy and chemotherapy versus any combination of radiotherapy and chemotherapy. Any combination of radiotherapy and biological agent versus placebo, no treatment or best supportive care. Any combination of radiotherapy and biological agent versus any combination of radiotherapy and biological agent. Any combination of radiotherapy and chemotherapy treatment and biological agent versus placebo, no treatment or best supportive care. Any combination of radiotherapy and chemotherapy treatment and biological agent versus any combination of radiotherapy and chemotherapy and biological agent.

Original languageEnglish
Article numberCD010584
Number of pages10
JournalCochrane Database of Systematic Reviews
Volume2013
Issue number6
DOIs
Publication statusPublished - 24 Jun 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this